Member Info for Radium1

Sounds like, Goodbye Totally Plc. The private sector is to be taken back under Public control with the latest proposed NHS reforms.
Boris Johnson is planning to roll back parts of the Conservatives’ NHS reforms in England, according to reports.
A leaked white paper details proposed changes to reduce the role of the private sector and scrap a system of contracts being put out to tender that has seen health groups competing against each other.
The proposals would see an end to reforms outlined in the 2012 Health and Social Care Act introduced by David Cameron’s government. That shake-up encouraged greater competition with the private sector….. moves that prompted criticism from professional bodies representing health workers.
https://www.msn.com/en-gb/news/other/boris-johnson-nhs-reforms-could-reduce-role-for-private-sector-in-health-service/ar-BB1drJ62

Sounds like, Goodbye Totally Plc. The private sector is to be taken back under Public control with the latest proposed NHS reforms.
Boris Johnson is planning to roll back parts of the Conservatives’ NHS reforms in England, according to reports.
A leaked white paper details proposed changes to reduce the role of the private sector and scrap a system of contracts being put out to tender that has seen health groups competing against each other.
The proposals would see an end to reforms outlined in the 2012 Health and Social Care Act introduced by David Cameron’s government. That shake-up encouraged greater competition with the private sector….. moves that prompted criticism from professional bodies representing health workers.
https://www.msn.com/en-gb/news/other/boris-johnson-nhs-reforms-could-reduce-role-for-private-sector-in-health-service/ar-BB1drJ62

Re Hull hospital. With all the spotlights on the Hull Hospital trial, the probability that the very first patient was given a placebo, is just about zero.

Infoking and oilornothing.....admonishments accepted.... Radium

In trying to assess a monitory valuation for Synairgen’s nebulised Interferon Beta, little thought has been given here to the potential added value that transpires from the possible, and indeed very probable, broader spectrum application/use for this treatment. Covid-19 will be with us for the foreseeable. If Synairgen’s treatment proves to be effective for covid-19 respiratory conditions, then it will likely have a broader spectrum application, meaning that it could be effective against other viral based respiratory infections as well, including those from influenza, which kills hundreds of thousands around the world every year. Conclusion….(assuming regulatory approval), there is a global addressable market out there well into the future for this treatment, other than just for Covid-19, and this little matter isn't being considered in the maths.

It may come as a surprise to some when I say that your annual flu vaccine has an efficacy of only (circa) 50%. Google it if you do not believe me.
So, when assessing the potential for regulatory approval for Synairgen’s nebulised Interferon Beta, it is worth highlighting here that it does not need to be anything like100% effective. This treatment will have considerable clinical value with a much lower efficacy and, because it showed such promise against the end point parameters set in the Phase 2 trial, 80%, if my memory serves me, I think the current Phase 3 trial stands a ‘better than good’ chance of producing results that will lead to regulatory approval in many countries. Consider also that the recently approved Dexamethasone treatment has shown to reduce mortality only by about one third...and it has side effects.
Phase 3 results should be known by the Summer but may be sooner depending on the speed of recruitment. Also, Synairgen’s Chief Exec said, its SG018 trial has been amended with the regulatory agencies "thereby reducing the number of patients required to complete the placebo-controlled trial from 900 patients to 610". Further, the primary endpoints have been changed to 'time to hospital discharge' and 'time to recovery'. Assessments for Long Covid-19 symptoms have been added, where patients are unable to shake off the effects of the virus months after initially falling ill, on day 60 and 90.
Chief Executive Richard Marsden said: "With this adaptation we should be able to reduce the time taken to complete the trial, which, together with an expedited review from the FDA, could allow us to get this therapy approved for patient use in Covid-19 more rapidly.
Worth noting. Covid-19 will be with us for the foreseeable. Any treatment that prevents hospitalisations, speeds recovery and saves lives will be of immense value in the globally battle against this disease. If Synairgen’s nebulised Interferon Beta treatment proves to be effective for covid-19, it will likely be effective against other viral based respiratory diseases too, including those from influenza. That means a global addressable market is out there well into the future for this treatment, other than just for Covid-19.
If regulatory approval is granted, not only will the share price respond accordingly but I believe Synairgen will be bought out in double quick time by a large Pharma, capable of getting this product to a global market as soon as possible.
As for making an investment choice…..it’s a roll of the dice based on what you know to date verses the probability of a successful phase 3 trial and subsequent regulatory approvals. Regulatory approval will send the share price vertical. Failure will return it to 35p. It is about as simple as that for me. On the basis of what I know to date, I have taken an educated punt that this treatment will be successful in its Phase 3 trials.

cont...depends on the recruitment success rate), stands a better than good chance of producing results that will lead to regulatory approvals in many countries.
Also, worth noting. Covid-19 will be with us for the foreseeable future. Any treatment that prevents hospitalisations, speeds recovery and saves lives will be of immense value globally in the battle against this disease.
If Synairgen’s nebulised interferon beta treatment proves to be effective for covid-19, it will likely be effective against other viral based respiratory diseases too, including influenza. That means a global addressable market is out there, well into the future for this treatment other than just for Covid-19. Not only will the share price respond accordingly but I firmly believe Synairgen will be bought out in very quick time by a big Pharma capable of getting this product to a global market as quickly as possible.
As for making an investment choice…..it’s a roll of the dice based on what you know to date verses the probability of a successful phase 3 trial and subsequent regulatory approvals in many different domains. Approval will send the sp vertical. Failure will return it to 35p. It’s about as simple as that for me. On the basis of what I know, I, personally have taken a educated punt this treatment will show success in Phase 3 trials.

It may come as a surprise to some when I say that your annual flu vaccine has an efficacy of only (circa) 50%. Google it if you don’t believe me. Therefore, keep in mind that this interferon treatment will be of significant clinical value with a similar efficacy. It does not need to be 100% effective in phase 3 trials to gain regulatory approvals.
So, in assessing the potential for regulatory approval for Synairgen’s Interferon Beta nebuliser it’s worth highlighting that it does not need to be anything like100% effective. This treatment will be of considerable clinical value with a much lower efficacy and since it was showing such good promise in the initial small-scale Phase 2 trial, 80%, if my memory serves me, I think the Phase 3 trial that has just started (results expected before Summer but could be earlier, depends on the recruitment success rate), stands a better than good chance of producing results that will lead to regulatory approvals in many countries.
Also, worth noting. Covid-19 will be with us for the foreseeable future. Any treatment that prevents hospitalisations, speeds recovery and saves lives will be of immense value globally in the battle against this disease.
If Synairgen’s nebulised interferon beta treatment proves to be effective for covid-19, it will likely be effective against other viral based respiratory diseases too, including influenza. That means a global addressable market is out there, well into the future for this treatment other than just for Covid-19. Not only will the share price respond accordingly but I firmly believe Synairgen will be bought out in very quick time by a big Pharma capable of getting this product to a global market as quickly as possible.
As for making an investment choice…..it’s a roll of the dice based on what you know to date verses the probability of a successful phase 3 trial and subsequent regulatory approvals in many different domains. Approval will send the sp vertical. Failure will return it to 35p. It’s about as simple as that for me. On the basis of what I know, I, personally have taken a educated punt this treatment will show success in Phase 3 trials.
It may come as a surprise to some when I say that your annual flu vaccine has an efficacy of only (circa) 50%. Google it if you don’t believe me. Therefore, keep in mind that this interferon treatment will be of significant clinical value with a similar efficacy. It does not need to be 100% effective in phase 3 trials to gain regulatory approvals.
So, in assessing the potential for regulatory approval for Synairgen’s Interferon Beta nebuliser it’s worth highlighting that it does not need to be anything like100% effective. This treatment will be of considerable clinical value with a much lower efficacy and since it was showing such good promise in the initial small-scale Phase 2 trial, 80%, if my memory serves me, I think the Phase 3 trial that has just started (results expected before Summer but could be earlier, cont.

Exract from Leeming…..Synairgen (SNG) is a potential lotto ticket.

The big hope here is for the therapeutics SNG001, which is on the FDA fast-track for possible review for FDA approval, provides a treatment for Covid-19. PHASE 2 has already demonstrated significant benefits, good enough to be published in the world-renown Lancet. Synairgen has teamed up with Parexel to enable a large amount of research to be conducted and ''enable rapid approvals worldwide.''

CEO Marsden says if all goes to plan ''we would have finished a phase II and III programme all in one year, which is very unusual.''

Fireworks are expected if the FDA gives the go-ahead having asked Synairgen to slightly modify and reduce the phase 3 parameters.

Also worthy of note is Pharmaxis, this should be licensed out to 3rd parties for which Synairgen gets 17% as an upfront milestone and royalties.

Key Event

If SNG001 gains FDA approval I seriously doubt Synairgen will survive as an independent entity, it will almost certainly be gobbled up by a larger pharmaceutical company. This is not just my opinion, it is the opinion of other city sources. If I am correct, then Synairgen will command multi-bag status from here, possible ahead of Open Orphan. Without checking, I think Numis has a valuation of £9.90p anyway.